English

Tekbiotech-Yeast and Phage Display CRO, Expert in Nano-body and Antibody Drug Development
  • How much do you know about ADC drug development?2026-05-07
    TekBiotech is committed to providing scientists worldwide with high-quality bispecific antibody-drug conjugate (BsADC) development services.
  • Eukaryotic System-Based Targeted Drug Discovery Platform: Yeast Display Technology2026-04-30
    TekBiotech can provide high-quality yeast display services to scientists worldwide.
  • Yeast Two-Hybrid Technology Reveals a Novel Mechanism of Wheat Disease Resistance: How TaPIR1 "Hijacks" TaHRP1 to Suppress Chloroplast Function?2026-04-28
    TekBiotech is committed to providing scientists worldwide with high-quality yeast one-hybrid technical services and yeast two-hybrid technical services.
  • Yeast Hybrid Library Construction: Smart Technology2026-04-23
    Tek Biotech can provide scientists worldwide with high-quality yeast hybrid library construction services.
  • New Molecular Interaction Technology: How Much Do You Know About Yeast Hybridization Technology?2026-04-21
    TekBiotech can provide high-quality yeast hybridization services to scientists worldwide.
  • A Promising Novel Cancer Therapeutic Strategy: Aptamer-Drug Conjugates (ApDCs)2026-04-16
    TekBiotech offers a range of screening methods, including MB-SELEX, Cell-SELEX, and CE-SELEX, to provide targeted aptamer discovery services tailored to various target types.
  • Novel Targeted Tumor Therapeutics: Efficacy of a Peptide-Drug Conjugate (PDC) in a Hepatocellular Carcinoma Model2026-04-14
    TekBiotech is dedicated to providing clients worldwide with comprehensive targeted peptide library construction and targeted peptide screening services.\n\n
  • Novel Cancer Therapeutic Strategy: Development of Bispecific Antibody-Drug Conjugates2026-04-09
    TekBiotech is committed to providing high-quality bispecific antibody-drug conjugate (BsADC) development services to scientists worldwide.
  • Nveiling the Molecular and Immunological Drivers of Antibody-Drug Conjugates (ADCs) in Cancer Treatment2026-04-07
    TekBiotech is dedicated to providing scientists worldwide with high-quality technical services including targeted antibody discovery, antibody humanization, ADC design and conjugation, cell killing assays, and animal model experiments.
  • A Novel Therapeutic Approach for Multiple Myeloma: Development of a CD38 and CD47 Bispecific Bipartopic Antibody2026-04-02
    TekBiotech is dedicated to providing high-quality bispecific antibody development services to scientists worldwide.
  • Total 16 PagePage: 5/16 PageHome45678Last Jump

    To experience the reliable service of Tekbiotech please subscribe: